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Abstract: The clinical diagnosis of Lyme borreliosis can be supported by various test meth-
odologies; test kits are available from many manufacturers. Literature searches were carried 
out to identify studies that reported characteristics of the test kits. Of 50 searched studies, 18 
were included where the tests were commercially available and samples were proven to be posi-
tive using serology testing, evidence of an erythema migrans rash, and/or culture. Additional 
requirements were a test specificity of ≥85% and publication in the last 20 years. The weighted 
mean sensitivity for all tests and for all samples was 59.5%. Individual study means varied from 
30.6% to 86.2%. Sensitivity for each test technology varied from 62.4% for Western blot kits, 
and 62.3% for enzyme-linked immunosorbent assay tests, to 53.9% for synthetic C6 peptide 
ELISA tests and 53.7% when the two-tier methodology was used. Test sensitivity increased 
as dissemination of the pathogen affected different organs; however, the absence of data on 
the time from infection to serological testing and the lack of standard definitions for “early” 
and “late” disease prevented analysis of test sensitivity versus time of infection. The lack of 
standardization of the definitions of disease stage and the possibility of retrospective selection 
bias prevented clear evaluation of test sensitivity by “stage”. The sensitivity for samples clas-
sified as acute disease was 35.4%, with a corresponding sensitivity of 64.5% for samples from 
patients defined as convalescent. Regression analysis demonstrated an improvement of 4% in 
test sensitivity over the 20-year study period. The studies did not provide data to indicate the 
sensitivity of tests used in a clinical setting since the effect of recent use of antibiotics or steroids 
or other factors affecting antibody response was not factored in. The tests were developed for 
only specific Borrelia species; sensitivities for other species could not be calculated.
Keywords: test sensitivity, 2 tier test, two-tier test, ELISA test, Western Blot, test specificity
The disease
Lyme borreliosis (LB) is an arthropod-borne zoonosis caused by several species of 
Borrelia bacteria. It can present with a wide range of symptoms, which are common 
to a number of other diseases. Soon after infection, the symptoms can be nonspecific 
and include fatigue. A characteristic erythema migrans (EM) dermatological lesion 
presents sometimes soon after infection in some cases of infection. Later symptoms 
reflect inflammation caused to specific organs and include cognitive dysfunction, 
arthralgia, myalgia, neuropathy, and ophthalmic and auditory symptoms.
The pathogen
LB is caused by bacteria of the genus Borrelia, of the family Spirochaetaceae in the 
phylum Spirochaetes, and is named after the French physician and biologist Amédée 
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Borrel (1867–1936) who worked on the classification of 
spirochetes and carried out studies on, in particular, Borrelia 
gallinarum (then named Spirillum gallinarum).1 At the time 
of writing, 21 species of Borrelia in the Borrelia burgdorferi 
sensu lato complex related to LB have been identified, many 
of which are known or potential pathogens to humans.2 They 
are adapted to be able to move between arthropod and mam-
malian hosts and express different outer surface proteins to 
avoid the immune systems of each host.
Disease stages
LB is a multisystemic infection, and dissemination from 
the site of a tick bite occurs rapidly by transportation of the 
spirochetes through the bloodstream. Invasion of specific 
organs and tissues may occur randomly and with no definite 
order of progression. Inflammation of specific organs and 
expression of symptoms can be dependent upon preexist-
ing conditions. Each study assessed for the present meta-
analysis classified samples into disease stages, sometimes 
including acute, chronic, early disseminated, early and 
late neurological, and early and late arthritis. There was 
no standard definition for any of these stages. The length 
of time for early and late stages was not uniformly defined 
and was frequently not defined at all. A discussion of LB 
transmission and difficulties in defining time of infection 
has been discussed in a prior publication by one of the 
authors (MJC).3
The possibility of bias resulting from the retrospective 
nature of the studies has been discussed in a recent analysis 
of both commercial and developmental test kits, including 
those in this analysis; all case–control studies (59 out of 59) 
had a high probability of bias in patient sampling and a high 
risk of bias in the timing and flow of the disease.4 Since there 
was no standardization for definitions for the disease stages, 
including timing for early and late disease, in the present 
study, the definitions provided by each author have been used 
together with summaries generated by combining symptoms 
where possible. However, because of these uncertainties, data 
for overall sensitivity for specific test kits and methodologies 
will have more validity than the data by disease stages.
Test methods for detection of 
Borrelia infections
Microscopy
Microscopy has been the “gold standard” method for detect-
ing and classifying bacterial infections since the father of 
microbiology, Antonie van Leeuwenhoek described bacteria 
viewed through his microscope in 1676. The method is still 
widely used for the diagnosis of disease and is widely used 
in the field of LB research during preparation of cultures 
for experimental work and for the production and control of 
materials for use in the manufacture of antigens, and occa-
sionally in clinical investigations.5 With culture enhancement 
based on a polymerase chain reaction (PCR) technique, the 
yield of blood cultures with microscopic detection can be 
increased to over 70%.6 The method is not generally used for 
clinical diagnosis as it requires highly trained technicians. 
A new fluorescent assay has been developed that makes the 
method more definitive using a molecular beacon-based 
multiplex real-time quantitative PCR assay to detect specific 
bacterial species.7
The majority of tests carried out for diagnosis of LB 
depend upon detecting antibodies created in response to the 
infection.
Enzyme-linked immunosorbent assay and 
immunofluorescence assay
The enzyme-linked immunosorbent assay (ELISA) is the 
primary test normally used to evaluate blood samples; it is 
used sometimes as a standalone test or as the first stage of 
a two-tier test. There are a number of embodiments of the 
basic technology used in research and commercial test kits. 
They are based on using native antigens derived from “whole 
cell” extracts, recombinant antigens, or synthetic peptides 
based on a conserved region of the VlsE (the variable surface 
antigen) of B. burgdorferi for the detection of immunoglobu-
lins.8 The tests are quantitative and give an indication of the 
concentration of antibodies in the sample. The Centers for 
Disease Control and Prevention (CDC) recommend that an 
immunofluorescence assay can be used instead of an ELISA 
as the first test in two-tier testing for Lyme disease. This 
indirect method has a number of limitations compared with 
the ELISA and is rarely used in human diagnostic testing 
for LB, although it is still used in veterinary practice in a 
number of European countries to detect antibodies against 
Borrelia species.9
Western blot
A second test commonly in use is the Western blot (WB), 
originally developed by Towbin et al.10,11 The majority 
of commercial Borrelia test kits use electrophoresis to 
separate antigens from known positive samples across a 
polymer strip. This is then processed with serum samples, 
and Borrelia antibodies that match the antigens on the 
strip will bind. After incubation using a substrate that will 
be dyed, the antibody/antigen complex can be visualized. 
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The dark bands on the strip can be compared with a stan-
dard provided by the manufacturer, and the density and 
scoring bands can be judged as positive if the density is 
greater than a reference band. There are many antibodies 
that can be expressed after infection with Borrelia. The 
probability that a given one is present and detectable by 
the test can be very low. Of more than 12 antibodies that 
can be present, the probability of detection of specific 
bands varies from a low of 0% to a high of 68%.12 As a 
result, positive interpretation of a WB strip requires more 
than one band to be present. For IgG test interpretation, 
some manufacturers specify that five or more of 10 criti-
cal bands must be positive for the test to be considered 
positive. Guidelines for IgM tests usually require that two 
or more bands are positive; however, a modified MiQ 12 
2000 standard for Germany required only one IgM band 
for a positive diagnosis.13 There have been attempts to stan-
dardize bands and proposals to increase the sensitivity.14 
Another adaptation of the technology uses antigens that 
are printed in strips on the polymer substrates, which are 
then reacted with patient serum and are more easily read 
manually or using a scanning densitometer. The selection 
of optical density thresholds is empirical and governed by 
the need to avoid cross-reactivity with other diseases while 
attempting to maintain a viable sensitivity. Variations of 
electroblotting include double blotting, pressure double 
blotting, electro-double blotting, slice blotting, tissue 
printing, native electrophoresis and Western blot (NEWeB), 
grid-immunoblotting, multiple antigen blot assay, multiple 
tissue WB, dot-immunobinding assay, the use of polymer 
immunocomplexes, blotting from PhastGel via ultrasound, 
and Eastern blotting.15 The WB kits are used as standalone 
tests or as the second stage of the two-tier protocol.
Selection of Borrelia species for extraction of antigens 
is based on “local” sources and a limited number of species. 
Test kits used in the USA typically use antigens from the 
B31 strain of B. burgdorferi sensu stricto, whereas those in 
Europe usually also include antigens derived from Borrelia 
afzelii and Borrelia garinii.
There are now at least nine species assigned to the LB 
group that are actual or probable pathogens.5,16–20 Sensitivity 
of WB tests is known to vary depending on the species pres-
ent in the sample. One study indicates that when an in-house 
test was prepared from local Borrelia species, the test was 
significantly more sensitive than a commercial test kit in use 
in that region.21 No published studies have been identified that 
characterize the sensitivity of commercial tests for species 
other than those included by the manufacturer.
Two-tier testing
At a meeting held by the Association of State and Territo-
rial Public Health Laboratory Directors in 1994, the CDC 
adopted a two-step methodology for defining LB cases for 
epidemiological studies.22 This requires a first-stage ELISA or 
immunofluorescence assay, and positive and equivocal samples 
are then tested using a WB confirmatory test (IgM and IgG 
WB if signs or symptoms have been present for up to 30 days 
[inclusive]; IgG WB if signs or symptoms have been present 
for more than 30 days). This was designed to standardize the 
methodology for testing and reporting LB throughout the USA 
and to minimize false positives. During one of the workshop 
sessions at this meeting, this methodology was recommended 
for diagnostic testing in clinical cases22 and has been widely 
accepted for that use, including by the Infectious Diseases Soci-
ety of America, British Infection Association, European Union 
Concerted Action on Lyme Borreliosis, and many others.23–25
Polymerase chain reaction
This technique is based on direct detection of DNA by ampli-
fication of small quantities of DNA fragments from a sample 
and comparison with a known DNA sequence.26,27 There are 
a number of modifications including quantitative PCR and 
real-time PCR. The test is moving out of the research labora-
tory into use to support clinical diagnosis. The search profiles 
did not identify any independent evaluation data. Some are 
shown in this analysis for comparison, but not included in 
the calculations of overall test sensitivities.
New testing technologies
There are a number of tests currently in use by laboratories 
for detecting LB infections that do not use antibody detec-
tion, including the enzyme-linked immunospot, lymphocyte 
transformation test, and culture-enhanced microscopy. These 
are based on detecting immune system activation or direct 
visualization of the bacteria. Another identifies Borrelia DNA 
fragments using electrospray ionization mass spectrometry, 
and others are in development.
There is preliminary evidence suggesting that newer 
technologies might have some advantages. For example, in a 
study of 54 consecutively presenting patients carried out by 
one of the authors (BKP), while 45 had negative WB results 
by the CDC criteria, 19 (42%) of these patients were positive 
according to the lymphocyte transformation test-memory 
lymphocyte immunostimulation assay.28 None of these newer 
tests is included in this analysis owing to a lack of sufficient 
independent studies of sensitivity and specificity at the time 
of preparation of this manuscript.
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Study selection
PubMed and Google Scholar were used with the search 
terms “Lyme disease OR borreliosis AND testing” to iden-
tify studies. All papers published since 1995 were selected 
for consideration. Data analysis and charting were carried 
out using software based on the Microsoft Excel platform.29
The studies were separated into two groups:
Group 1
Studies were included in the analysis where the following 
criteria were met:
1. Samples were proven to be positive for LB based on one 
or more of the following: clinical records of an EM rash; 
positive serology; culture; samples meeting the CDC 
criteria (generally being an EM rash or being two-tier 
positive) or CDC-certified panels with samples charac-
terized by them as positive, negative, or equivocal. Full 
criteria are available for your reference in  Centers for 
Disease Control and Prevention.30
2. The tests were commercially available.
3. The specificity was ≥85%.
These are shown in Table 1 with test method, sample type/
disease stage, and performance.31–47
Group 2
Studies were excluded where one or more the inclusion 
criteria was absent.
These are given in detail in Table 2 which includes per-
formance data and the reasons for exclusion. They included 
studies that used in-house developed tests or experimental 
interpretation methodologies, those where samples were 
from patients with suspected LB but not definitively proven, 
where there were no specificity data, and one study where 
interpretation criteria were modified from the manufacturers’ 
specified method were all excluded.28,48–74
Some studies included a mixture of samples, with some 
meeting Group 1 inclusion criteria, and other samples 
selected based on clinical symptoms alone. For example, 
Porwancher et al41 used acute and convalescent samples that 
were from culture-confirmed cases, and later-stage samples 
based solely on clinical symptoms. In such cases, only data 
meeting Group 1 criteria were included.
Sensitivity and specificity
The most important parameters that define the characteristics of 
a test are the sensitivity, which is the probability that a positive 
sample will be defined as positive by the test, and  specificity, the 
probability that a negative sample will be defined as negative, 
usually defined as 1 − (false positive probability).
In antibody tests, there is a relationship between sen-
sitivity and specificity as described by the receiver operat-
ing curve. As a test is made more specific, the sensitivity 
decreases and vice versa. This is important in the context of 
the studies selected in this analysis. It is possible to increase 
the sensitivity of a test by lowering detection thresholds; how-
ever, in doing so, the probability of false positives increases. 
There are many process parameters that affect the sensitivity 
of ELISA and WB tests including serum dilution, WB incu-
bation times, WB antigen concentration, band selection, etc.
Where the kits provided by the manufacturer had separate 
IgM and IgG antibody tests, the highest sensitivity reported 
was used to determine study means. In some studies, the 
sensitivity based on either IgM or IgG antibody detection 
was reported, and this value was used.
Specificity data are those reported by the researchers. In 
some cases, the specificity was determined using blood donor 
samples from healthy people in LB endemic areas, in some 
cases from donors in areas where LB was nonendemic (for 
example, Branda et al),33 whereas in other cases, controls 
included samples from patients with known diseases that 
could cross-react with the test kits. Engstrom et al,54 for 
example, included a small group of samples from patients 
who had been diagnosed with other diseases including 
Epstein–Barr viral infection, syphilis, rheumatoid arthritis, 
multiple sclerosis, leptospirosis, systemic lupus erythema-
tosus, group A streptococcal infection, and relapsing fever. 
The possibility exists that samples from patients with LB 
were included in the groups used to determine specificity. 
For example, many studies indicate that healthy controls from 
general populations and at-risk groups are seropositive for 
LB75,76 and that blood donor samples contain significant num-
bers that are seropositive.77,78 This could result in unnecessary 
desensitization of tests to meet specificity targets.
Data extraction and analysis
There was no standardized method for carrying out the evalu-
ations or recording data, and so data were extracted manu-
ally from the documents and entered into Microsoft Excel 
worksheets. This allowed computation and preparation of a 
standard format giving sample size, positive samples, and 
percentage of positive results. This was used to define the 
sensitivity for each stage of disease and for each test method. 
To compute the overall sensitivity for all studies and for all 
subgroups, the weighted average of sample size and positive 
samples of subgroups was used.
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Table 1 Studies included in the analysis
Study Year Patient 
enrollment
Disease  
stage
Test Mean of 
subgroup 
positives
Subgroup 
sample 
size
Sens Spec Number 
of test 
kits
Comment
Bacon et al31 2003 CDC All Two-tier 186.3 280 66% 99% 8 Multiple samples  
from some subjects. Only 
IgM result included. IgG 
sensitivity was 31%.
Klempner et al37 2001 CDC Chronic WB IgG 14.0 21 67% 100% 1
Mogilyansky et al40 2004 CDC panel All WB 14.3 18 79% 89% 7 C6 data excluded with 
specificity of 73%.
Tilton et al43 1997 CDC panel All WB 30.7 46 67% Note 
1
6 Test runs with low 
specificity (60.0%, 68.2%) 
excluded.
Smit et al42 2015 Seropositive All IgM/IgG 8.5 21 40% 99% 4
Branda et al33 2010 CDC/EM All EIA/WB/ 
two-tier
28.2 45 69% 98% 3
Wormser et al47 2012 EM and/or 
seropositive
EM Two-tier 83.0 158 53% 99% 5 Only two-tier results 
included. ELISA test 
“indeterminate” was 
included with “positive” 
results for WB.
Dessau81 2013 CSF positive Neuro-
borreliosis
ELISA 37.0 48 69% 97% 2 CSF-positive samples. IgG 
data only used.
Branda et al34 2013 EM/culture/
seropositive
All ELISA,  
C6, WB
51.3 64 80% 99% 8 Data for European 
samples tested with US 
B31 test kits not included
Goossens et al36 1999 EM EM ELISA,  
WB
13.9 26 48% 88% 15 Only IgM result included. 
IgG sensitivity was lower 
at 16%
Johnson et al80 1996 EM All Two-tier 37.1 58 64% 96% 2 Only two-tier study 
included. See excluded 
studies.
Tjernberg et al44 2007 EM Acute ELISA, C6 55.8 158 35% 87% 3
Trevejo et al45 1999 EM All Two-tier 37.0 121 31% 100% 3
Binnicker et al32 2008 EM and/or 
culture
All WB IgM 16.3 28 58% 95% 4
Gomes-Solecki 
et al35
2002 EM and  
culture positive
EM ELISA 56.0 65 86% 100% 2 Only commercial test 
included and only 
samples with clear 
definition of status of 
sample.
Marangoni et al38 2005 Culture EM ELISA, C6 27.7 45 40% 90% 5 Data are for samples at 
enrollment. Follow-up 
data not included.
Marangoni et al39 2008 Culture All ELISA 44.0 66 67% 97% 4
Porwancher et al41 2011 Culture All All 45.3 80 57% 96% 4 Best-case WB and two-
tier selected.
Notes: Enrollment criteria – CDC: samples met CDC criteria; EM rash and/or seropositive: using a two-tier test with approved test kits; EM: samples from patients with 
documentation of EM rash in clinical records; culture: samples were positive using culture and microscopy; CDC panel: samples obtained from the CDC and certified to 
meet the criteria defined.
Abbreviations: sens, weighted mean test sensitivity; spec, test specificity; WB, Western blot; EM, erythema migrans; CDC, Centers for Disease Control and Prevention; 
EIA, immunofluorescence assay; ELISA, enzyme-linked immunosorbent assay; CSF, cerebrospinal fluid; C6, synthetic C6 peptide ELISA.
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Table 2 Studies not meeting inclusion criteria
Study Year Patient 
enrollment
Disease stage Test Sens Spec Comment
Ang et al48 2011 Clinical All ELISA, VlsE, C6 44% 86% Samples from patients with suspected Lyme disease.
Burbelo et al49 2010 Clinical All VOVO, C6, 
ELISA
98% 99% In-house developed test.
Busson et al50 2012 All ELISA, WB, 
two-tier
98% 91% Samples from patients with suspected Lyme 
disease. Duplicate samples from patients. Kits 
supplied by manufacturers.
Coulter et al51 2005 Suspected All ELISA 45%–72% ND No specificity data. Study of culture sensitivity 
and algorithm using culture plus PC.
Craven et al52 1996 CDC All ELISA/WB 57%–100% 71%–98% In-house tests. Work carried out in 1992, tests 
not commercially available. Interlaboratory 
study. Cross-reactive samples not used for 
some specificity characterization.
Dessau et al53 2010 Clinical All ELISA local 
antigens
9.2% ND Data are best-case IgM tests. IgG was lower 
sensitivity, specificity was 98%.
Engstrom et al54 1995 EM 
documented
Early and EM In house 43% 97% Test development.
Eshoo et al55 2012 EM/CDC All PCR/EIS-MS 62% 100% PCR ESI-MS.
Goettner56 2005 EM Early Western blot 81% 99% In-house developed test.
Heikkilä et al58 2003 Seropositive Arthritis ELISA 37%–96% ND Results from experiments with eleven different 
antigens.
Johnson et al80 1996 Clinical All Culture/two-
tier
81% 90% Possible sample bias described by authors.
Koidl et al59 2013 Clinical All IgM 32% ND Samples from patients with suspected Lyme disease.
Lawrenz et al61 1999 All EM ELISA 70% 98% In-house developed test.
Liang et al8 1999 Seropositive All C6 89% 99% In-house developed test.
Liang et al60 2000 All All C6 84% 99% In-house developed test.
Liu et al62 2013 All All ELISA, WIB 67% 94% In-house developed test.
Nordberg et al63 2012 Well 
characterised
Neuroborreliosis Elispot 36% 82% Samples from patients with suspected Lyme 
disease.
Nowakowski 
et al64
2001 EM/CDC EM Culture 48% ND Culture test not commercially available.
Nowakowski 
et al64
2001 EM/CDC EM PCR 72% ND PCR tests not generally available.
Nowakowski 
et al64
2001 EM/CDC EM Two-tier 68% ND Specificity not determined in the study.
Puri et al28 2014 Clinical Consecutive 
presentation
LTT MELISA ND ND Study compared WB and LTT test results. 
Absolute sensitivity and specificity were not 
investigated.
Rebman et al65 2015 EM rash >5 cm EM All 41% ND Commercial laboratory. No data for specificity.
Robertson 
et al66
2000 EM or Clinical All Unspecified 
WB
19%–100% 44%–100% 2-, 3-, and 4-band interpretation criteria, not 
5 band.
Ryffel et al67 1999 Seropositive All WB ND ND Protein-based study for Borrelia species.
Schulte-Spectel 
et al68
2003 Seropositive Neuro Whole cell 
blot
86% 86% Test development.
Seriburi et al69 2012 Clinical All two-tier ND ND False-positive study of clinical cases. No 
sensitivity data.
Skarpaas et al70 2007 Definite LNB Neuro Quick C6 Sera 98% 61% Excluded for low specificity (61% with serum).
Skogman et al71 2008 CSF positive NB ELISA 82% 100% Only data for in-house test is available.
Smismans et al72 2006 Seropositive All Study mean 77% 84% Borderline results counted positive. Specificity 
less than 85%.
Steere et al73 2008 CDC/EM All C6/two-tier 45% 100% First-stage test was in-house ELISA.
Vermeesch et al46 2009 Seropositive/CSF Neurological C6 68% ND No specificity data.
Wormser et al74 2008 CDC/EM All C6/two-tier 69.5%/38.9% ND No specificity data.
Wormser et al47 2012 EM All All 53% ND No specificity data.
Study mean 69.3% 91.5% Specificity mean based on limited reported data.
Abbreviations: ESI-MS, electrospray ionization mass spectrometry; sens, weighted mean test sensitivity; spec, test specificity; WB, Western blot; EM, erythema migrans; 
CDC, Centers for Disease Control and Prevention; ELISA, enzyme-linked immunosorbent assay; CSF, cerebrospinal fluid; PCR, polymerase chain reaction; LTT, lymphocyte 
transformation test; LNB, Lyme neuroborreliosis; ND, not determined; C6, synthetic C6 peptide ELISA.
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Results and discussion
A summary of the tests, including sensitivity and specificity 
data, is shown in Figures 1–5 and Tables 3 and 4. Included 
are the sample sources, disease stage and test methods used, 
and the sensitivity confidence intervals.
The weighted mean sensitivity for all studies and for all 
disease stages is 59.5%, and the weighted mean specificity is 
96.1%. In comparison, the mean sensitivity of the excluded 
Group 2 studies was 69.3%; however, 13 studies did not 
report specificity data, and others demonstrated specificities 
as low as 61.5%. Low specificity is associated with increased 
test sensitivity.
The mean sensitivity for individual studies varied from 
a low of 30.6% (Trevejo et al45) to a high of 80.2% (Mogi-
lyansky et al40). The lowest sensitivity for a specific test was 
7.4% (Branda et al33). This was a WB test used to identify IgG 
antibodies in samples defined by the authors as acute stage.
The most sensitive test methodology was WB with a 
weighted mean of studies of 62.4%, and varied from a low of 
53.5% to a high of 76.6%. The weighted mean of all ELISA 
tests was 62.3%, which was not statistically different from 
the WB test, with a low of 45.0% and a high of 82.2%. The 
mean sensitivity of the six studies using synthetic C6 peptide 
ELISA tests was 53.9%, with a low of 42.1% and a high of 
53.9%. Finally, the mean of the two-tier tests was 53.7%, with 
a low of 38.9% and a high of 67.5%. These data are shown 
in Table 3 and Figures 3–6.
Studies were excluded where the specificity was <85%. 
Four studies were excluded based on this. Smismans et al72 
was excluded as the study mean specificity was 74% and 
sensitivity was 77%. High specificity was obtained using a 
two-tier test with the first-stage test optical density threshold 
lowered. Nordberg et al63 was excluded as this study had a 
specificity of 82%; the sensitivity was also low at 36% and 
would have depressed the study mean sensitivity. Craven et 
al’s52 study had a low specificity of 71% with a sensitivity of 
51%, which would not significantly bias the overall results 
of this study. Finally, Skarpaas et al’s70 study demonstrated 
a high sensitivity of 98% but a very low specificity of 61%, 
which if used would lead to very high levels of false positives.
It is frequently stated that IgM antibody levels will be 
higher in early-stage disease and IgG antibody levels will be 
higher in later-stage disease. This was not always supported 
by the data. Branda et al34 reported a sensitivity of an IgM test 
as 80% for neuroborreliosis with the corresponding IgG test 
having a sensitivity of 60%. Some studies did demonstrate 
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Figure 1 Studies included in the analysis. Weighted sensitivity for each study.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f G
en
er
al
 M
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
5.
19
8.
8.
19
2 
on
 1
2-
Ja
n-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of General Medicine 2016:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
434
Cook and Puri
86.2%
59.0%
52.9%
64.4%
45.0%
66.7%
75.0%
77.1%
62.3%
Gomes-Solicki et al,35 2002
Goossens et al,36 1999
Trevejo et al,45 1999
Marangoni et al,38 2005
Tjernberg et al,44 2007
Marangoni et al,39 2008
Branda et al,33 2010
Dessau,81 2013
Weighted mean
10% 20% 30% 40% 50% 60%
Sensitivity
S
tu
dy
70% 80% 90% 100%
Figure 2 ELISA sensitivity.
Abbreviation: ELISA, enzyme-linked immunosorbent assay.
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Figure 3 Synthetic C6 peptide ELISA test sensitivity.
Abbreviation: ELISA, enzyme-linked immunosorbent assay.
a higher sensitivity for IgM tests with early-stage disease, 
for example, Goossens et al36 showed IgM sensitivity of 
59% and IgG sensitivity of 48% using a whole-cell ELISA, 
and IgM sensitivity of 48% and IgG of 15.5% using a WB 
test. However, Bacon et al31 reported a sensitivity of 43.8% 
with acute stage disease using an IgG test and 18.8% using 
an IgM test, and Liu et al62 for early-stage EM rash samples 
showed an IgG test sensitivity of 78.8%, much higher than 
the IgM test at 57.7%.
Some studies defined a positive result based on either an 
IgM or an IgG response, whereas others reported sensitivity 
based on a single test, IgM or IgG. There was a significantly 
higher test sensitivity when the IgM and IgG positives were 
combined. Branda et al34 found that the sensitivity of a WB 
test was 53.1% based on IgM response, 67.2% for an IgG 
response, and 81.3% when either the IgM or IgG response 
was used.
In the case of early-stage disease where there was a record 
of an EM rash, the sensitivity based on IgM was 35%, 35% for 
an IgG response, and 55% for combined IgM or IgG response. 
Similarly, for later-stage neuroborreliosis, the sensitivity for 
IgM was 80%, for IgG 60%, and for combined IgM or IgG 
87%. Marangoni et al38 demonstrated for culture confirmed 
samples an IgM sensitivity of 67%, for IgG 33% , and for 
combined IgM or IgG 71%.
These results indicate that laboratories where the selec-
tion of an IgM or IgG test is based on clinical records that 
suggest early- or late-stage disease have a lower sensitivity 
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Figure 4 Western blot test sensitivity.
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Figure 5 Two-tier sensitivity test.
Table 3 Test sensitivity summary
Test method Sensitivity 95% CI
ELISA 62.3% 56.6%–68.1%
C6 53.9% 48.3%–61.1%
Western Blot 62.4% 54.2%–70.7%
Two-tier 53.7% 49.9%–57.4%
ALL 59.5% 55.6%–63.5%
Abbreviations: ELISA, enzyme-linked immunosorbent assay; C6, synthetic C6 
peptide ELISA; CI, confidence interval; WB, Western blot.
Table 4 Test sensitivity for disease stage
Disease stage Sensitivity 95% CI
EM 46.5% 41.1%–51.9%
Acute/early 35.4% 30.5%–40.2%
Convalescent 64.5% 57.3%–71.7%
Neurological 87.3% 71.4%–97.5%
Arthritis 95.8% 81.8%–100.0%
Neurological/arthritis 92.2% 78.4%–100.0%
Abbreviations: CI, confidence interval; EM, erythema migrans.
than those running both tests and accepting either test as 
indicative of disease.
Within the limits already discussed regarding the lack 
of definitions and standardization of disease stage and the 
high risk of bias in all studies, the tests were most sensitive 
at 89.7% when neurological and/or arthritic symptoms were 
present. The sensitivity for samples from patients at the con-
valescent stage of the disease was 64.5%, and the sensitivity 
for samples at the acute stage was 35.4%. It should be noted 
that these results are based on samples that were defined as 
positive by the definitive existence of an EM rash, culture of 
Borrelia, or positive with a prior serology test, or combina-
tions of these. These data and confidence intervals are shown 
in Table 4 and Figures 6–8.
The lack of antibody response in early-stage disease is 
well recognized by the main guidelines, all of which define 
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Figure 6 Sensitivity for acute stage samples.
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Figure 7 Sensitivity of convalescent samples.
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Figure 8 Sensitivity for neurological/arthritis/carditis samples.
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the need to diagnose and treat LB if an EM rash is present, 
usually giving specific instructions that serology tests are 
not necessary.23,24,79 Two studies gave details of length of 
time between EM rash onset and sample extraction/testing. 
Marangoni et al38 indicate that patients enrolled in the study 
had a duration of EM rash ranging from 5 to 106 days with a 
mean of 16 days. However, only the mean sensitivity of 60.1% 
(95% confidence interval 38.6%–84.4%) with testing carried 
out at enrollment was presented. Wormser et al47 gave details 
of the “days postonset of symptoms”; however, the sensitiv-
ity data presented did not show sensitivity versus postonset 
time, and only overall averages were shown. The sensitivity 
achieved with a history of an EM rash using a synthetic C6 
peptide ELISA and WB test in a two-tier protocol was 34.5%, 
for a false-negative rate of 65.5%.
There was no evidence that the commercial test kit 
sensitivity has improved significantly over time. Linear 
regression of data from all included studies is shown in 
Figure 9, which demonstrates an increase in test sensitivity 
of 4% points over the 20-year study period. These results 
lend support to the recently published conclusion of Stricker 
and Johnson14 to the effect that “FDA-cleared commercial 
serological testing for Lyme disease is inadequate for the 
diagnosis of the disease”.
Conclusion
All studies included in this analysis used test samples that 
were predefined as positive for LB infection either by a prior 
serological test that was positive, or a clinical record showing 
a history of an EM rash, or culture confirmed, or a combina-
tion of these. Based on this, the sensitivity determined for 
the tests with these samples would be expected to be close 
to 100%. This is not the case, as has been demonstrated in 
this analysis.
y=0.0011x–1.6543 
0%
10%
20%
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40%
50%
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Trend line
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Figure 9 Test sensitivity versus year of publication.
The sensitivity of an individual test was as low as 7.4%. 
The mean sensitivity of all test kits with all samples was 
59.5%, and ranged from 30.6% to 86.2%.
The technologies with the highest sensitivity were WB, 
with a mean sensitivity of all test kits of 62.4%, and ELISA 
at 62.3%. The mean of tests using the synthetic C6 peptide 
ELISA was 53.9%, followed by the two-tier methodology 
with a sensitivity of 53.7%.
There was a lack of standardization of disease “stages” 
and of the definition of early and late disease. Along with the 
potential for bias in sample categorization, the sensitivity of 
the tests presented for disease stages should be considered as 
indicative and not definitive. The studies do demonstrate that 
sensitivity increases with severity of symptoms and dissemi-
nation to joints, the heart, and the central nervous system.
The sensitivities achieved by these studies do not repre-
sent test performance in clinical settings. The methods for 
selection of samples used in these studies eliminated samples 
from patients demonstrating a weak antibody response. Also, 
clinical samples will include those taken soon after infec-
tion before antibodies have developed; those from patients 
already treated with antibiotics or steroids, which suppress 
antibody production and depress test sensitivity; and those 
from patients with weakened immune systems. Quantification 
of the impact on test sensitivity was not possible since no data 
were presented by the individual study authors for the effects 
of any of these variables. Additional issues include quality 
control practices of testing facilities used by clinicians and 
issues such as sample shipment and storage. Currently, there 
are 21 named species assigned to the LB group, of which nine 
are proven or suspected pathogens, and other Borrelia species 
that generate Lyme-like symptoms such as B. miyamotoi. It 
was not possible to determine from the studies identified 
in this analysis, nor from other sources, the sensitivity of 
commercial test kits when patient samples were infected by 
species other than B. burgdorferi sensu stricto, B. afzelii, or 
B. garinii. It is recommended that studies be carried out to 
determine test sensitivities for other species and improved 
test methods actively pursued and approved for general use.
An important clinical implication of our conclusion that 
current Lyme testing lacks sensitivity is that many genuine 
cases of LB may be underdiagnosed. Based on the findings 
of our meta-analysis, we would recommend that clinicians 
do not assume that negative laboratory investigation results 
exclude a diagnosis of Lyme disease.
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